Water, propanediol, glycerin, sodium lauryl methyl isethionate, cocamidopropyl betaine, sodium methyl oleoyl taurate, lauryl glucoside, coco-glucoside, d-panthenol, xanthan gum, cetyl hydroxyethylcellulose, glyceryl caprylate, glyceryl undecylenate, sorbitan oleate decylglucoside crosspolymer, Ascorbic Acid, Lavandula angustifolia (Lavender) Flower Oil, Citrus aurantium dulcis (Orange) Peel Oil KOA LIFE was founded by entrepreneurial twin duo, Kymber and Alexis McClay (aka the Naven Twins), as a safe daily natural alternative to chemical products
Microdosing involves administering a much lower amount of GLP-1 medication, typically 10% to 25% of a standard starting dose, to capture therapeutic benefits without aggressive physical changes
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights to reveal your peptide-pathway predispositions, including factors affecting medication efficacy and side-effect risk
In some cases, adjusting the dose of oral progesterone may be necessary, but this should only be done in consultation with a healthcare provider
